Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04118803
Other study ID # RTSY04 - OSIRIS
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 31, 2020
Est. completion date May 30, 2025

Study information

Verified date June 2023
Source MicroPort CRM
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The purpose of the study is to assess the incidence of inappropriate shocks at 2 years, in a population of patients undergoing a generator replacement (VR/DR/CRT) or upgrade from a previously implanted ICD (VR/DR)


Description:

All subjects will be included during an inclusion visit (within 7 days post generator replacement or upgrade), and followed up at a post replacement visit (1 - 6 months post replacement or upgrade), at 12, 18 and 24 months post replacement or upgrade. These follow-up visits will be performed in-clinic except for the 18 months post replacement or upgrade visit, which could be performed through device remote monitoring. Additional follow-ups can be performed at physician's discretion. Data on reportable adverse events will be collected throughout the study. All study data will be collected using an EDC system. All delivered anti-tachycardia therapies (shock or ATP) will be reviewed by an independent board of experts in order to evaluate appropriateness. The programming of the device parameters is at physician's discretion (suggested settings is slow VT monitoring zone 150 - 185 bpm with 30 cycles persistence, VT zone 185 - 230 bpm with 16 cycles persistence, remote monitoring activated).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 881
Est. completion date May 30, 2025
Est. primary completion date May 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Any subject that had an ICD/CRT-D replacement/upgrade according to the latest relevant clinical guidelines with a MicroPort CRM ICD / CRT-D for less than 7 days 2. Signed and dated the informed consent form Exclusion Criteria: 1. RV lead replacement 2. Previous ICD/CRT-D inactivated or already explanted 3. Active myocarditis 4. Primary prevention for Arrhythmogenic Ventricular Cardiomyopathy, Ion channelopathies, Hypertrophic Cardiomyopathy and Infiltrative or Inherited Cardiomyopathy. 5. Heart transplant (done or on waiting list) or implanted with a ventricular assist device (VAD) 6. Already included in an Interventional study that could confound the results of this study 7. Inability to understand the purpose of the study or to meet follow-up visits as defined in the investigational plan 8. Minor age (<18 years) or under guardianship or kept in detention 9. Ongoing drug or alcohol addiction or abuse which would interfere with the subject's ability to be compliant with the study. 10. Life expectancy less than 1 year 11. Pregnant or breast feeding

Study Design


Related Conditions & MeSH terms

  • Inappropriate Shocks From Implanted Defibrillator

Intervention

Device:
ICD replacement or upgrade
Currently, it is common for patients to survive beyond their initial prophylactic ICD generator. It is unclear whether further benefit related to inappropriate shocks or ATP is derived from long-term device therapy, particularly if there has been a change in the patient's cardiovascular condition.

Locations

Country Name City State
Austria Universitätsklinik Innsbruck - Kardiologie und Angiologie Innsbruck
Austria Akademisches Krankenhaus Wien Vienna
Austria Landesklinikum Wiener Neustadt Wiener Neustadt
Belgium UZ Brussel Jette
Belgium UCL Mont-Godinne Yvoir
France CH du Pays d'Aix Aix-en-Provence
France CH Annecy Genevois Annecy
France Clinique Rhône Durance Avignon
France CHU Brest Brest
France Hôpital d'Instruction des Armées Percy Clamart
France CHU de Grenoble Grenoble
France CH de Libourne Robert Boulin Libourne
France CHU Dupuytren Limoges
France Hôpital Nord Marseille
France Hôpital Privé Clairval Marseille
France Clinique du Millénaire Montpellier
France CHU Nice Nice
France CHU Groupe HU Caremeau Nîmes
France CH de Perpignan CHG St Jean Perpignan
France CHU Poitiers Poitiers
France CHU - Hôpital Nord - Saint-Étienne Saint-Étienne
France CHI Toulon La Seyne Sur Mer Toulon
France Centre Hospitalier de Rangueil Toulouse
France Centre Hospitalier de Valence Valence
Germany UKSH Schleswig Holstein Campus Kiel Kiel
Germany Deutsches Herzzentrum München Munich
Germany Cardiologicum Pirna
Germany Katharinen Hospital Unna Unna
Italy Ospedale L. Bonomo Andria
Italy Azienda Ospedaliera G. Moscati Avellino
Italy Ospedale Clinicizzato SS. Annunziata Chieti
Italy Presidio Ospedaliero di Chioggia Chioggia
Italy Ospedale Santa Maria dei Battuti Conegliano
Italy Ospedale San Salvatore L'Aquila
Italy Grande Ospedale Metropolitano Niguarda Ca Granda Milan
Italy Ospedale S. Gerardo Monza
Italy Ospedale Policlinico Federico II Napoli
Italy Ospedale Giovanni Paolo II Ragusa
Italy Ospedale Giuseppe Mazzini Teramo
Italy Azienda Ospedaliero Universitaria Ospedali Riuniti Di Trieste Trieste
Netherlands Isala Klinieken Zwolle
Portugal Centro Hospitalar Lisboa Norte - Hospital de Santa Maria Lisbon
Spain Hospital General Universitario de Alicante Alicante
Spain Hospital Universitario de La Ribera Alzira
Spain Hospital Universitario Virgen de las Nieves Granada
Spain Hospital Universitario Virgen de la Victoria Malaga
Spain Hospital General Universitario de Valencia Valencia
Spain Complejo Hospitalario Universitario de Vigo Vigo
Switzerland Universitätsspital Basel Basel
Switzerland GZO Spital Wetzikon AG Wetzikon
United Kingdom Belfast Health & Social Care Trust Belfast
United Kingdom Papworth Hospital NHS Foundation Trust Cambridge
United Kingdom Northampton General Hospital NHS TRUST Northampton
United States The University of Chicago Medicine Hospital Chicago Illinois
United States Broward Health Medical Center Fort Lauderdale Florida
United States St. Mary Medical Center Langhorne Pennsylvania
United States Loyola University Medical Center Maywood Illinois
United States Rutgers New Jersey Medical School Newark New Jersey

Sponsors (1)

Lead Sponsor Collaborator
MicroPort CRM

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  France,  Germany,  Italy,  Netherlands,  Portugal,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of inappropriate shocks This endpoint will assess the incidence of inappropriate shocks, in a population of patients undergoing a generator replacement (VR/DR/CRT) or upgrade from a previously implanted ICD (VR/DR). 2 years after replacement or upgrade